Biodegradable and Inherently Fluorescent pH-Responsive Nanoparticles for Cancer Drug Delivery.


Journal

Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 30 03 2022
accepted: 13 06 2022
pubmed: 29 6 2022
medline: 8 11 2022
entrez: 28 6 2022
Statut: ppublish

Résumé

The development of two novel pH-only and pH- and thermo-responsive theranostic nanoparticle (NP) formulations to deliver an anticancer drug and track the accumulation and therapeutic efficacy of the formulations through inherent fluorescence. A pH-responsive formulation was synthesized from biodegradable photoluminescent polymer (BPLP) and sodium bicarbonate (SBC) via an emulsion technique, while a thermoresponsive BPLP copolymer (TFP) and SBC were used to synthesize a dual-stimuli responsive formulation via free radical co-polymerization. Cisplatin was employed as a model drug and encapsulated during synthesis. Size, surface charge, morphology, pH-dependent fluorescence, lower critical solution temperature (LCST; TFP NPs only), cytocompatibility and in vitro uptake, drug release kinetics and anticancer efficacy were assessed. While all BPLP-SBC and TFP-SBC combinations produced spherical nanoparticles of a size between 200-300 nm, optimal polymer-SBC ratios were selected for further study. Of these, the optimal BPLP-SBC formulation was found to be cytocompatible against primary Type-1 alveolar epithelial cells (AT1) up to 100 μg/mL, and demonstrated sustained drug release over 14 days, dose-dependent uptake, and marked pH-dependent A549 cancer cell killing (72 vs. 24% cell viability, at pH 7.4 vs. 6.0). The optimal TFP-SBC formulation showed excellent cytocompatibility against AT1 cells up to 500 μg/mL, sustained release characteristics, dose-dependent uptake, pH-dependent (78% at pH 7.4 vs. 64% at pH 6.0 at 37°C) and marked temperature-dependent A549 cancer cell killing (64% at 37°C vs. 37% viability at pH 6.0, 41°C). In all, both formulations hold promise as inherently fluorescent, stimuli-responsive theranostic platforms for passively targeted anti-cancer therapy.

Identifiants

pubmed: 35764754
doi: 10.1007/s11095-022-03317-8
pii: 10.1007/s11095-022-03317-8
pmc: PMC9633373
mid: NIHMS1827010
doi:

Substances chimiques

Antineoplastic Agents 0
Polymers 0
Drug Carriers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2729-2743

Subventions

Organisme : NIAAA NIH HHS
ID : R21 AA029750
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR072731
Pays : United States
Organisme : NIAMS NIH HHS
ID : 1R01AR072731-01
Pays : United States
Organisme : NIAAA NIH HHS
ID : R21AA029750-01
Pays : United States
Organisme : CPRIT
ID : RP210206
Organisme : Rhode Island Foundation
ID : #20174376

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Mol Pharm. 2008 Jul-Aug;5(4):505-15
pubmed: 18672949
Biomaterials. 2012 Mar;33(8):2508-20
pubmed: 22197569
Biomaterials. 2013 Jan;34(1):1-10
pubmed: 23044041
Mater Sci Eng C Mater Biol Appl. 2021 Jun;125:112100
pubmed: 33965110
Int J Pharm. 2014 May 15;466(1-2):1-7
pubmed: 24607216
Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):1-6
pubmed: 18439063
Chem Biol Interact. 2014 Sep 5;220:102-15
pubmed: 24992398
J Control Release. 2011 Feb 28;150(1):56-62
pubmed: 21070826
Int J Pharm. 2012 May 10;427(2):435-42
pubmed: 22342467
Free Radic Biol Med. 2006 Jun 1;40(11):1914-28
pubmed: 16716893
Front Cell Dev Biol. 2019 Jan 29;7:4
pubmed: 30761299
Proc Natl Acad Sci U S A. 2009 Jun 23;106(25):10086-91
pubmed: 19506254
Mol Cancer. 2003 Jan 03;2:1
pubmed: 12537587
Biointerphases. 2013 Dec;8(1):19
pubmed: 24706136
PLoS One. 2019 May 31;14(5):e0217640
pubmed: 31150477
Pharm Res. 2006 Aug;23(8):1835-41
pubmed: 16858650
Commun Biol. 2020 Mar 3;3(1):95
pubmed: 32127636
Front Bioeng Biotechnol. 2019 Nov 22;7:353
pubmed: 31824940
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Drug Deliv. 2008 May;15(4):235-43
pubmed: 18446569
J Biomater Sci Polym Ed. 2004;15(5):585-94
pubmed: 15264660
Front Physiol. 2013 Dec 05;4:354
pubmed: 24367336
Curr Treat Options Oncol. 2007 Feb;8(1):38-46
pubmed: 17634834
Respirology. 2006 Jan;11 Suppl:S12-5
pubmed: 16423262
Sci Rep. 2017 Oct 16;7(1):13249
pubmed: 29038584
Adv Healthc Mater. 2012 Jul;1(4):450-6
pubmed: 23061030
Molecules. 2012 May 10;17(5):5564-91
pubmed: 22576228
J Biosci Bioeng. 2005 Jul;100(1):1-11
pubmed: 16233845
Acta Biomater. 2017 Mar 1;50:361-369
pubmed: 28069502
Nanotheranostics. 2020 Jan 1;4(1):1-13
pubmed: 31911890
Nano Rev. 2010;1:
pubmed: 22110864
Small. 2017 Mar;13(10):
pubmed: 28026115
JAMA. 2021 May 11;325(18):1829-1830
pubmed: 33787821
Theranostics. 2013;3(3):152-66
pubmed: 23471164
Biomed Environ Sci. 2015 May;28(5):341-51
pubmed: 26055561
Cancer. 1974 Jul;34(1):122-9
pubmed: 4599460
Biopolymers. 2007;88(3):325-39
pubmed: 17167795
Artif Cells Nanomed Biotechnol. 2018 Aug;46(5):949-958
pubmed: 28687054
Front Oncol. 2022 Mar 22;12:855019
pubmed: 35392227
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Biomaterials. 2018 Jul;170:70-81
pubmed: 29653288
J Pharm Sci. 2011 Feb;100(2):655-66
pubmed: 20799367

Auteurs

Kalindu Perera (K)

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, Rhode Island, 02881, USA.

Dat X Nguyen (DX)

Bioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Graduate Biomedical Engineering Program, The UT Southwestern Medical Center at Dallas, Dallas, Texas, 75390, USA.

Dingbowen Wang (D)

Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania, 16802, USA.

Aneetta E Kuriakose (AE)

Bioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Graduate Biomedical Engineering Program, The UT Southwestern Medical Center at Dallas, Dallas, Texas, 75390, USA.

Jian Yang (J)

Department of Biomedical Engineering, Pennsylvania State University, University Park, Pennsylvania, 16802, USA.

Kytai T Nguyen (KT)

Bioengineering Department, The University of Texas at Arlington, Arlington, Texas, 76019, USA.
Graduate Biomedical Engineering Program, The UT Southwestern Medical Center at Dallas, Dallas, Texas, 75390, USA.

Jyothi U Menon (JU)

Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Kingston, Rhode Island, 02881, USA. jmenon@uri.edu.
Department of Chemical Engineering, University of Rhode Island, Kingston, Rhode Island, 02881, USA. jmenon@uri.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH